囊泡包装以支持儿科患者对华法林的坚持:一个试点回顾性研究
Leanne T Meakins1,2, Joel R Livingston1,2, Mary E Bauman1,2
1KidClot Program, Stollery Children's Hospital, Edmonton, Alberta, Canada.
Paediatrics & child health
|August 4, 2025
概括
囊泡包装 (BP) 可能会改善儿童对华法林的坚持. 这项研究发现,BP减少了错过的剂量和提醒,趋势是治疗范围 (TTR) 的时间增加.
科学领域:
- 儿科药理学 儿科药理学
- 药物坚持研究 药物坚持研究
- 临床药房实践中的临床药房实践.
背景情况:
- 华法林是为特定的儿科适用处方,但坚持是具有挑战性的.
- 儿童不服从华法林可能会导致严重的并发症.
- 由于剂量调整,泡包装 (BP) 不是华法林的标准,但可能会提高粘附性.
研究的目的:
- 评估泡包装 (BP) 在儿科门诊患者的华法林管理中的有效性.
- 评估血压对药物坚持和临床结果的影响.
主要方法:
- 对儿童 (18个月至18岁) 进行了回顾性图表审查,这些儿童的华法林粘附性较差,转换为BP.
- 数据包括国际正常化比率 (INR) 提醒,遗漏剂量和6个月前后BP的不良事件.
- 治疗范围中的时间 (TTR) 被分析为安全性和有效性的衡量标准.
主要成果:
- 这项综述包括11名儿科患者.
- 使用BP与INR提醒率下降30%和遗漏的华法林剂量下降20%有关.
- 在BP后,TTR中位数增加了11.61%,尽管这在统计学上并不显著 (P=0.1602).
结论:
- 囊包装 (BP) 是一个可行的工具来支持儿童的华法林管理.
- 护理人员报告BP是有益的,并指出改善TTR和减少医疗保健提供者的工作负担的趋势.
更多相关视频
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Blinding
2.6K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.6K
Drug Delivery: Parenteral Route
834
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
834
One-Compartment Open Model for IV Bolus Administration: General Considerations
318
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
318
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
140
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
140


